Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling

Next Previous
X
Search
Trial Profile

Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 25 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Lenzilumab (Primary) ; Ascorbic acid; Ascorbic acid
  • Indications Chronic myelomonocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms PREACH-M

    • Most Recent Events

    • 12 Dec 2023 Results (n=15) shoeing cytokine profiles and systemic C-reactive protein levels in newly diagnosed CMML patients treated with Lenzilumab, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results describing improvements in variant allele frequencies (VAF) for RAS-pathway mutations and hematologic improvements associated with LENZ/AZA treatment in CMML, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Interim results (n=11) presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top